Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.

[1]  K. Ohtomo,et al.  Gadobenate dimeglumine as a contrast agent for MRI of the mouse liver , 2007, NMR in biomedicine.

[2]  A. Persson,et al.  Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects , 2007, Acta radiologica.

[3]  Yusuke Inoue,et al.  Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. , 2007, Experimental hematology.

[4]  K. Ohtomo,et al.  Imaging living mice using a 1‐T compact MRI system , 2006, Journal of magnetic resonance imaging : JMRI.

[5]  R. Goldin,et al.  Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research , 2006, International journal of experimental pathology.

[6]  I. B. Borel Rinkes,et al.  Mouse Models of Colorectal Cancer and Liver Metastases , 2005, Digestive Surgery.

[7]  Maximilian F Reiser,et al.  Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. , 2005, Radiology.

[8]  K. Koike,et al.  Role of hepatitis C virus in the development of hepatocellular carcinoma: Transgenic approach to viral hepatocarcinogenesis , 2002, Journal of gastroenterology and hepatology.

[9]  M. Peters.  Animal models of autoimmune liver disease , 2002, Immunology and cell biology.

[10]  T Haishi,et al.  Development of a 1.0 T MR microscope using a Nd-Fe-B permanent magnet. , 2001, Magnetic resonance imaging.

[11]  V. Lorusso,et al.  Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). , 1999, Journal of computer assisted tomography.

[12]  Takamichi Murakami,et al.  Evaluation of Regional Liver Function by Gadolinium-EOB-DTPA-Enhanced MR Imaging , 1999, Digestive Diseases and Sciences.

[13]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[14]  A. Spinazzi,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[15]  K J Wolf,et al.  Detection of focal liver lesions: CT of the hepatobiliary system with gadoxetic acid disodium, or Gd-EOB-DTPA. , 1997, Radiology.

[16]  W Krause,et al.  Ytterbium- and dysprosium-EOB-DTPA. A new prototype of liver-specific contrast agents for computed tomography. , 1996, Investigative radiology.

[17]  G. Morana,et al.  Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application. , 1996, Radiology.

[18]  E. Rummeny,et al.  Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. , 1996, Radiology.

[19]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[20]  G. Schuhmann-Giampieri.  Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. , 1993, Investigative radiology.

[21]  H. Weinmann,et al.  Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. , 1992, Radiology.

[22]  H. Weinmann,et al.  A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRI , 1991, Magnetic resonance in medicine.

[23]  G. Vittadini,et al.  Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent. , 1990, Investigative radiology.

[24]  J. Watkins.  Exposure of rats to inhalational anesthetics alters the hepatobiliary clearance of cholephilic xenobiotics. , 1989, The Journal of pharmacology and experimental therapeutics.

[25]  Stuart Young,et al.  MRI Measurement of Hepatocyte Toxicity Using the New MRI Contrast Agent Manganese Dipyridoxal Diphosphate, a Manganese/Pyridoxal 5‐Phosphate Chelate , 1989, Magnetic resonance in medicine.

[26]  L. Smith,et al.  Liver Circulation and Function during Isoflurane and Halothane Anesthesia , 1984, Anesthesiology.